PNV Stock Overview
Designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.98 |
| 52 Week High | AU$2.78 |
| 52 Week Low | AU$1.34 |
| Beta | 1.72 |
| 11 Month Change | -8.14% |
| 3 Month Change | -21.00% |
| 1 Year Change | 46.84% |
| 33 Year Change | 35.97% |
| 5 Year Change | 10.34% |
| Change since IPO | 2,094.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| PNV | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -3.2% | 0.5% | 0.9% |
| 1Y | 46.8% | 14.8% | 18.4% |
Return vs Industry: PNV exceeded the Australian Medical Equipment industry which returned 14.8% over the past year.
Return vs Market: PNV exceeded the Australian Market which returned 18.4% over the past year.
Price Volatility
| PNV volatility | |
|---|---|
| PNV Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: PNV has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PNV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 254 | Swami Raote | polynovo.com |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products.
PolyNovo Limited Fundamentals Summary
| PNV fundamental statistics | |
|---|---|
| Market cap | AU$1.37b |
| Earnings (TTM) | AU$5.26m |
| Revenue (TTM) | AU$103.23m |
260.0x
P/E Ratio13.2x
P/S RatioIs PNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNV income statement (TTM) | |
|---|---|
| Revenue | AU$103.23m |
| Cost of Revenue | AU$16.41m |
| Gross Profit | AU$86.82m |
| Other Expenses | AU$81.56m |
| Earnings | AU$5.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0076 |
| Gross Margin | 84.11% |
| Net Profit Margin | 5.10% |
| Debt/Equity Ratio | 3.6% |
How did PNV perform over the long term?
See historical performance and comparison